Navigation Links
Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010
Date:11/2/2010

.prop15='106547453';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  
Download image

POINT RICHMOND, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Thursday, November 11, 2010 at 5:00 p.m. Eastern time to discuss its third quarter 2010 financial results.  The conference call will follow the release of the Transcept third quarter 2010 financial results after the close of market that day.

(Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101102/SF93452LOGO)Conference Call Information Date: Thursday, November 11, 2010Time: 5:00 p.m. ESTDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call throug
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
3. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
4. Transcept Pharmaceuticals to Present at BIO Investor Forum
5. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
6. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
7. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
8. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
9. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
11. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , Kalifornien, 20. Mai 2013 ... das Unternehmen die CE-Kennzeichnung für die SL-Produktfamilie ... von Aneurysmen erhalten hat. Das Unternehmen hat ... mit der kontrollierten Einführung dieser neuen Modelle ... SL-Produktfamilie auch ein verbessertes Handling, das es ...
(Date:5/20/2013)... DIEGO , May 20, 2013 Enrollment ... Elcelyx Therapeutics, Phase 2b dose-finding clinical trial of product ... metformin, the foundational treatment for Type 2 diabetes. Elcelyx ... multicenter U.S. program in June. Results of the trial,s ... expected in late summer, and the read-out for long-term ...
(Date:5/20/2013)... , May 20, 2013  AbbVie (NYSE: ... of a Phase 3 clinical study called SONAR ... the effects of the investigational compound atrasentan - when ... kidney disease in patients with stage 2 to ... diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... NATICK, Mass., Jan. 4, 2011 Boston Scientific Corporation ... of its acquisition of Sadra Medical, Inc. of Los ... announced on November 19, 2010.  Under the terms of ... the remaining 86 percent of Sadra Medical,s equity not ...
... and Company) (NYSE: BDX ), a leading global medical ... Annual J. P. Morgan Healthcare Conference on Monday, January 10, 2011, ... BD,s presentation can be accessed from the BD corporate website at ... January 17, 2011.   About BDBD is ...
Cached Medicine Technology:Boston Scientific Completes Acquisition of Sadra Medical 2Boston Scientific Completes Acquisition of Sadra Medical 3Boston Scientific Completes Acquisition of Sadra Medical 4
(Date:5/20/2013)... HealthEconomics.Com , the global leader ... present a new breakthrough in digital marketing and communications ... the reach of traditional, real-world trade shows and conferences ... feel, and benefits of a physical trade show, but ... hours a day, seven days a week, and three ...
(Date:5/20/2013)... that improved health care and significant reductions in drug ... relationship between physicians and drug company representatives who promote ... , This system, which has been in place for ... up to date on new medications, and always provided ... on the newest drugs, as well as other supplies ...
(Date:5/20/2013)... Las Vegas, NV (PRWEB) May 20, 2013 ... Health IT to improve the exchange of healthcare information, ... the creation of the WEDI ICD-10 State Collaborative ... organizations and their members in order to increase efficiencies ... ICD-10 compliance. , The goal of the new initiative ...
(Date:5/20/2013)... Irving, Texas (PRWEB) May 20, 2013 ... and Phytel, the leader in automated, provider-led population ... health systems to effect change and successfully pursue ... of advisory services and technology to accelerate the ... of the VHA IMPERATIVTM performance improvement suite of ...
(Date:5/20/2013)... May 20, 2013 The Multiple System ... the launch of its new Multiple System Atrophy ... few years, The MSA Coalition’s grass roots fundraising has ... mission beyond patient/caregiver support to now include education, advocacy ... all donations received by The Coalition go directly into ...
Breaking Medicine News(10 mins):Health News:HealthEconomics.Com Launches HE-Xpo, an Online Virtual Trade Show, Educational Center and Exhibit Hall at Major Pharmaceutical Industry Meeting 2Health News:HealthEconomics.Com Launches HE-Xpo, an Online Virtual Trade Show, Educational Center and Exhibit Hall at Major Pharmaceutical Industry Meeting 3Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3Health News:WEDI Launches New ICD-10 State Collaborative Initiative to Increase Efficiencies and Reduce Compliance Time and Costs 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 2Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 3Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 4Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 5
... , FRIDAY, April 15 (HealthDay News) -- Teens who ... for traffic crashes, a new study finds. But starting ... attention and reduce impulsiveness, another study finds. In 2008, ... Virginia Beach, Va., was about 41 percent higher than for ...
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) ... an artificial pancreas for the management of type 1 diabetes, ... sugar control and reduce the risk of dangerous low blood ... that the overall time that plasma glucose levels were in ...
... A comprehensive investigation of brain tissue donated to the ... tissue donation program, determined that one-third of the brain ... from the California State Department of Developmental Services revealed ... with both autism and epilepsy than for individuals with ...
... , THURSDAY, April 14 (HealthDay News) -- Kidney ... the new organ can develop accelerated narrowing of the ... lead to organ rejection. That,s the finding of ... biopsies from 99 kidney transplant patients -- 40 with ...
... calls are a common drain on the manpower and ... that identified Baltimore City,s top 911 callers and coupled ... cutting the number of such calls while helping callers ... conceived and implemented by the non-profit agency Baltimore HealthCare ...
... the risks and benefits of a medical intervention is not ... according to an article in the Hastings Center Report ... to disclose quantitative data to patients to help them make ... determine the best way to provide information to patients. ...
Cached Medicine News:Health News:Early School Start Tied to More Teen Crashes: Study 2Health News:Latest Artificial Pancreas Trials Reduce Risk of Low Blood Sugar 2Health News:Latest Artificial Pancreas Trials Reduce Risk of Low Blood Sugar 3Health News:Mortality rate is increased in persons with autism who also have epilepsy 2Health News:Targeting top 911 callers can trim cost, improve patient care 2Health News:Targeting top 911 callers can trim cost, improve patient care 3Health News:Too Much Information? Risk-benefit data does not always lead to informed decision-making 2Health News:Too Much Information? Risk-benefit data does not always lead to informed decision-making 3
... Autotransfusion System processes blood collected from ... red blood cells for return to ... This is achieved with only one ... bowl design, coupled with sophisticated software, ...
The Wixson Hip Positioner is used for stable positioning of a patient during total hip and revision surgery. It is designed to be placed on top of the operating table....
Stryker Instruments InterPulse System advances the ease and performance of battery powered irrigation for Orthopaedics, Trauma, and Wound Care....
... VersaNail System is a complete system of ... use with TTC fusion surgery. The system ... and integrates clinical research and engineering with ... every patient is different, and because the ...
Medicine Products: